<?xml version='1.0' encoding='utf-8'?>
<document id="28783867"><sentence text="Absence of Effect of Intravaginal Miconazole, Clindamycin, Nonoxynol-9, and Tampons on the Pharmacokinetics of an Anastrozole/Levonorgestrel Intravaginal Ring."><entity charOffset="34-44" id="DDI-PubMed.28783867.s1.e0" text="Miconazole" /><entity charOffset="46-57" id="DDI-PubMed.28783867.s1.e1" text="Clindamycin" /><entity charOffset="59-70" id="DDI-PubMed.28783867.s1.e2" text="Nonoxynol-9" /><entity charOffset="114-125" id="DDI-PubMed.28783867.s1.e3" text="Anastrozole" /><entity charOffset="126-140" id="DDI-PubMed.28783867.s1.e4" text="Levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e0" e2="DDI-PubMed.28783867.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e0" e2="DDI-PubMed.28783867.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e0" e2="DDI-PubMed.28783867.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e0" e2="DDI-PubMed.28783867.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e0" e2="DDI-PubMed.28783867.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e1" e2="DDI-PubMed.28783867.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e1" e2="DDI-PubMed.28783867.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e1" e2="DDI-PubMed.28783867.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e1" e2="DDI-PubMed.28783867.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e2" e2="DDI-PubMed.28783867.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e2" e2="DDI-PubMed.28783867.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e2" e2="DDI-PubMed.28783867.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e3" e2="DDI-PubMed.28783867.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s1.e3" e2="DDI-PubMed.28783867.s1.e4" /></sentence><sentence text="A study was performed to investigate the effect of an intravaginally administered antimycotic, an antibiotic, and a spermicide plus the co-usage of tampons on the pharmacokinetics (PK) of levonorgestrel (LNG) and anastrozole (ATZ) administered as an intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day"><entity charOffset="188-202" id="DDI-PubMed.28783867.s2.e0" text="levonorgestrel" /><entity charOffset="204-207" id="DDI-PubMed.28783867.s2.e1" text="LNG" /><entity charOffset="213-224" id="DDI-PubMed.28783867.s2.e2" text="anastrozole" /><entity charOffset="226-229" id="DDI-PubMed.28783867.s2.e3" text="ATZ" /><entity charOffset="314-316" id="DDI-PubMed.28783867.s2.e4" text="LNG" /><entity charOffset="292-294" id="DDI-PubMed.28783867.s2.e5" text="ATZ" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e0" e2="DDI-PubMed.28783867.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e0" e2="DDI-PubMed.28783867.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e0" e2="DDI-PubMed.28783867.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e0" e2="DDI-PubMed.28783867.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e0" e2="DDI-PubMed.28783867.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e0" e2="DDI-PubMed.28783867.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e1" e2="DDI-PubMed.28783867.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e1" e2="DDI-PubMed.28783867.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e1" e2="DDI-PubMed.28783867.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e1" e2="DDI-PubMed.28783867.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e1" e2="DDI-PubMed.28783867.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e2" e2="DDI-PubMed.28783867.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e2" e2="DDI-PubMed.28783867.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e2" e2="DDI-PubMed.28783867.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e2" e2="DDI-PubMed.28783867.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e3" e2="DDI-PubMed.28783867.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e3" e2="DDI-PubMed.28783867.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e3" e2="DDI-PubMed.28783867.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e5" e2="DDI-PubMed.28783867.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28783867.s2.e5" e2="DDI-PubMed.28783867.s2.e4" /></sentence><sentence text=" In this parallel-group, randomized, open-label study, healthy premenopausal women received an IVR as the main treatment" /><sentence text=" Comedications were administered on 3 consecutive evenings during treatment with IVR on days 9-11 (group A, 400 mg miconazole; group B, 100 mg clindamycin; group C, 75 mg nonoxynol-9); tampon co-usage (group D) was performed on days 20-23"><entity charOffset="115-125" id="DDI-PubMed.28783867.s4.e0" text="miconazole" /><entity charOffset="143-154" id="DDI-PubMed.28783867.s4.e1" text="clindamycin" /><entity charOffset="162-163" id="DDI-PubMed.28783867.s4.e2" text="C" /><entity charOffset="171-182" id="DDI-PubMed.28783867.s4.e3" text="nonoxynol-9" /><entity charOffset="1-11" id="DDI-PubMed.28783867.s4.e4" text="C" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e4" e2="DDI-PubMed.28783867.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e4" e2="DDI-PubMed.28783867.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e4" e2="DDI-PubMed.28783867.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e4" e2="DDI-PubMed.28783867.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e4" e2="DDI-PubMed.28783867.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e0" e2="DDI-PubMed.28783867.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e0" e2="DDI-PubMed.28783867.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e0" e2="DDI-PubMed.28783867.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e0" e2="DDI-PubMed.28783867.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e1" e2="DDI-PubMed.28783867.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e1" e2="DDI-PubMed.28783867.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e1" e2="DDI-PubMed.28783867.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e2" e2="DDI-PubMed.28783867.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s4.e2" e2="DDI-PubMed.28783867.s4.e3" /></sentence><sentence text=" The primary PK parameter was the average plasma concentration (Cav,ss ) of ATZ and LNG at defined intervals, mainly prior to, during, and up to 7 days after the start of comedication"><entity charOffset="84-84" id="DDI-PubMed.28783867.s5.e0" text="LNG" /><entity charOffset="76-76" id="DDI-PubMed.28783867.s5.e1" text="ATZ" /><entity charOffset="64-64" id="DDI-PubMed.28783867.s5.e2" text="C" /><pair ddi="false" e1="DDI-PubMed.28783867.s5.e2" e2="DDI-PubMed.28783867.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28783867.s5.e2" e2="DDI-PubMed.28783867.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s5.e2" e2="DDI-PubMed.28783867.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28783867.s5.e1" e2="DDI-PubMed.28783867.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s5.e1" e2="DDI-PubMed.28783867.s5.e0" /></sentence><sentence text=" Fifty-two subjects were included, and at least 11 subjects per group completed the treatments" /><sentence text=" Overall, the medications and comedications were safe and well tolerated" /><sentence text=" Very similar ATZ and LNG plasma levels were observed across all groups"><entity charOffset="22-22" id="DDI-PubMed.28783867.s8.e0" text="LNG" /><entity charOffset="14-14" id="DDI-PubMed.28783867.s8.e1" text="ATZ" /><pair ddi="false" e1="DDI-PubMed.28783867.s8.e1" e2="DDI-PubMed.28783867.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s8.e1" e2="DDI-PubMed.28783867.s8.e0" /></sentence><sentence text=" The calculated ratios of Cav,ss confirmed the absence of PK interactions because all relevant point estimates and 90% confidence intervals were within the range of 0"><entity charOffset="26-28" id="DDI-PubMed.28783867.s9.e0" text="C" /></sentence><sentence text="800-1" /><sentence text="250, which is typically used in bioequivalence studies" /><sentence text=" These results demonstrate the absence of PK interactions between ATZ/LNG released from IVR and the tested antibiotic, antimycotic, spermicide, and tampons"><entity charOffset="70-70" id="DDI-PubMed.28783867.s12.e0" text="LNG" /><entity charOffset="66-66" id="DDI-PubMed.28783867.s12.e1" text="ATZ" /><pair ddi="false" e1="DDI-PubMed.28783867.s12.e1" e2="DDI-PubMed.28783867.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28783867.s12.e1" e2="DDI-PubMed.28783867.s12.e0" /></sentence><sentence text=" Therefore, no restrictions for the use of the IVR are needed to continue the clinical program intended to treat endometriosis symptoms" /><sentence text="" /></document>